[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitat Jaume I\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":405},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,52,82,119,142,172,202,222,242,268,297,324,353,380],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100596874","efficacy-of-a-personalized-response-based-transdiagnostic-intervention-for-emotional-disorders-delivered-via-the-internet-a-protocol-for-an-adaptive-randomized-controlled-trial-100596874",false,"NCT07051148","Efficacy of a Personalized, Response-based Transdiagnostic Intervention for Emotional Disorders Delivered Via the Internet: A Protocol for an Adaptive Randomized Controlled Trial","Inclusion Criteria:\n\n* Spanish speakers\n* OASIS score +\u002F= 8\n* ODSIS score +\u002F= 7\n* Access to Internet\n* Email\n\nExclusion Criteria:\n\n* Severe mental disorder: schizophrenia\u002Fbipolar disorder\n* Active substance abuse\n* High suicide risk\n* Ongoing psychological\u002Fpharmacological treatment\n* Interfering physical illness","ALL","18 Years","70 Years",{"count":19,"type":20},366,"ESTIMATED","INTERVENTIONAL",[23],"NA","This adaptive randomized controlled trial evaluates the efficacy of a transdiagnostic, internet-delivered psychological intervention for emotional disorders, tailored to patient´s early clinical response. 366 adults with clinically significant symptoms of depression and\u002For anxiety will begin a 12 module self-applied program. Based on sympton reduction after the first three modules, participants will be classified as early or late responders and randomized into different experimental arms. The main hypothesis is that a hybrid format (self-applied modules plus synchronous sessions with a therapist) will yield better outcomes for late responders. Outcomes include symptom reduction, emotional regulation and internet based therapheutic alliance.",[26,27,28],"Emotional Disorders","Anxiety","Depression, Unipolar",[30,31,32,33,26,34,35,36,37,38,39],"transdiagnostic","internet based therapy","anxiety","depression","adaptive intervention","blended treatment","digital interventions","personalization","personalized treatment","adaptive trial","NOT_YET_RECRUITING","2026-05-21",{"date":43,"type":44},"2026-05-27","ACTUAL",{"date":46,"type":20},"2027-05-01",{"date":48,"type":20},"2030-07",{"name":50,"class":51},"Universitat Jaume I","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100482975","efficacy-of-a-transdiagnostic-group-treatment-for-emotional-disorders-applied-in-blended-format-a-controlled-study-100482975","NCT05569018","Efficacy of a Transdiagnostic Group Treatment for Emotional Disorders Applied in Blended Format: a Controlled Study.","Efficacy of a Group Treatment Based on Transdiagnostic Perspective for Emotional Disorders and Applied in Blended Format: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Being 18 years old or more.\n* DSM-5 (APA, 1013) diagnostic criteria for emotional disorder (panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, major depressive disorder, dysthymia, obsessive-compulsive disorder, non-specified anxiety disorder, non-specified depressive disorder).\n* Good understanding of Spanish.\n* Access to the Internet and email address.\n* Informed consent to participate.\n\nExclusion Criteria:\n\n* Diagnosis of a severe mental disorder (psychotic disorder, bipolar disorder, substance and\u002For alcohol dependence).\n* High risk of suicide.\n* Having a serious medical illness or other condition that prevents treatment from being carried out.\n* Receiving another psychological treatment during the study period.\n* Changes and\u002For increases in pharmacological treatment during the study period (a decrease is accepted).",{"count":60,"type":20},144,[23],"This study will consist in a randomized controlled clinical trial (RCT) to test the efficacy of a blended group transversal protocol (BLGr-TP) compared to a face-to-face group transversal protocol (FFGr-TP).\n\nThe main aims of the study are the following:\n\n* To analyze the differential efficacy of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders in aspects of clinical measures, as well as in terms of retention and dropout rate and adherence.\n* To analyze the differential acceptability of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders.\n\nIn addition, it is intended to carry out a study of mediators and moderators of the efficacy of both interventions.\n\nThe established hypotheses in relation to the main goals are:\n\n* Both treatment modalities (FFGr-TP and BLGr-TP) will achieve improvements in the symptoms of emotional disorders, reflected in the scores of the clinical measures.\n* The BLGr-TP will show equivalent efficacy to the FFGr-TP.\n* The BLGr-TP will show an acceptability comparable to the face-to-face protocol. Both modalities will be well valued by the participants.\n* In both treatment modalities, the changes achieved are expected to be maintained over time (3, 6 and 12 months).",[64,65],"Anxiety Disorders","Depressive Disorders",[67,68,69,70,71],"Cognitive-Behavioral Therapy","Transdiagnostic CBT","Blended CBT","Group CBT","Emotional disorders","RECRUITING","2026-04-28",{"date":75,"type":44},"2026-05-05",{"date":77,"type":44},"2024-11-23",{"date":79,"type":20},"2027-07",{"name":50,"class":51},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":15,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":81},"100634343","active-breaks-and-executive-function-in-scholars-100634343","NCT07538453","Active Breaks and Executive Function in Scholars","Active-breaks, Learning, Creativity and Emotional Health in Preadolescent Students (ACTISTOP)","ACTISTOP","Inclusion Criteria:\n\n* Students enrolled in the 5th and 6th grades of primary education in the city of Castellón, with continuous academic progression and no history of grade retention.\n* Students without diagnosed physical, neurological, or cognitive disorders.\n\nExclusion Criteria:\n\n* Students with a history of grade retention.\n* Students with diagnosed learning difficulties or neurodevelopmental disorders.\n* Students presenting any medical or psychiatric disease.\n* Students undergoing chronic pharmacological treatment.",true,"11 Years","12 Years",{"count":94,"type":20},114,[23],"This study aims to examine whether short bouts of exercise (10 minutes) performed during the school day can improve thinking skills, creativity and emotional wellbeing in primary school children. Specifically, children aged 11-12 years will be randomly assigned to perform either a short aerobic exercise break, a strength-based exercise break, or a seated control activity. The study will evaluate how these 10 minutes activity breaks influence attention, working memory, creativity, and emotional wellbeing state after completing cognitively demanding tasks. The findings will help to identify effective strategies to integrate physical activity into the classroom to enhance learning and overall well-being in school settings.",[98,99,100],"Creativity","Executive Function (Cognition)","Psychological Wellbeing",[102,103,104,105,106,107,108,109,110],"cognition","attention","creativity","exercise","memory","sedentarism","physical activity","Inhibition","emotions","2026-04-15",{"date":113,"type":44},"2026-04-20",{"date":115,"type":44},"2026-03-26",{"date":117,"type":20},"2026-06",{"name":50,"class":51},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":81},"100619476","cost-effectiveness-and-implementation-of-a-transdiagnostic-internet-based-intervention-for-emotional-disorders-in-community-care-100619476","NCT07345117","Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Community Care.","From Research to Clinical Practice: Implementation of an Internet-based Transdiagnostic Treatment Program for Emotional Disorders in Primary Care (TREAT-ED)","TREAT-ED","Patient Inclusion Criteria:\n\n* Over 18 years of age.\n* Meet the diagnostic criteria for an anxiety or depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n* Understand and read Spanish or Catalan.\n* Have access to the Internet and an email address\n* Give informed consent.\n\nPatient Exclusion Criteria:\n\n* Diagnosis of schizophrenia, bipolar disorder, or alcohol or substance dependence.\n* High risk of suicide.\n* Presence of a medical condition that prevents psychological treatment.\n* Receiving other psychological treatment (other than TAU or the online program) during the study.\n* For participants in the online treatment condition with pharmacological treatment, this must be stabilized (doses cannot be changed or increased during the study, only reduced).\n\nInclusion Criteria for mental health Professionals:\n\n* They work at centers participating in the study.\n* They agree to participate in the study.\n* They sign an informed consent form.",{"count":128,"type":20},200,[23],"Emotional disorders (ED) are one of the leading causes of disability. They are highly prevalent and have an impact on quality of life. Addressing them places an overload on the National Health System (NHS), generating waiting lists and limiting appropriate care. The need for cost-effective solutions has led to the consideration of the transdiagnostic approach and the use of digital solutions. Both perspectives have demonstrated efficacy in a large number of randomized clinical trials. As a result, investment in digital health interventions is on the rise to improve access to care in overburdened healthcare systems. However, their integration and implementation in health systems remains limited. Implementation Science emerges to facilitate the integration of interventions into clinical practice through specific strategies that overcome barriers and optimize their sustainability. The objective of this project is to examine the effectiveness, economic costs and feasibility of implementing an online psychological treatment program for emotional disorders in mental health services. The Mutua and UJI teams have already carried out the transfer of the online program. In order to facilitate the adoption and sustainability of this program and that it can be used by mental health professionals in daily practice, a hybrid design 1 study will be carried out in which not only the efficacy but also the possibility of adoption and the analysis of economic costs in comparison with the usual treatment will be evaluated.",[26,132,133,64],"Depression Anxiety Disorder","Depression Disorders","2026-03-17",{"date":136,"type":44},"2026-03-18",{"date":138,"type":20},"2026-04-01",{"date":140,"type":20},"2029-01-01",{"name":50,"class":51},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100628412","multimodal-intervention-for-persistent-musculoskeletal-pain-in-primary-care-100628412","NCT07461298","Multimodal Intervention for Persistent Musculoskeletal Pain in Primary Care","Effectiveness of a Multimodal Intervention Based on Pain Neuroscience Education, Therapeutic Exercise and Healthy Lifestyle Promotion in Patients With Persistent Musculoskeletal Pain in Primary Care: A Multicenter Randomized Controlled Trial","DolorAP","Inclusion Criteria:\n\n* Adults aged between 18 and 70 years\n* Diagnosis of nonspecific persistent musculoskeletal pain lasting at least 6 months\n* Receiving care in participating primary care centers\n* Ability to understand study procedures and provide written informed consent\n* Ability to complete self-administered questionnaires\n\nExclusion Criteria:\n\n* Specific musculoskeletal pathology requiring specialized treatment (e.g., fracture, inflammatory rheumatic disease, malignancy)\n* Neurological disorders affecting movement or pain perception\n* Severe psychiatric disorders that may interfere with participation\n* Participation in another structured pain management program during the study period\n* Cognitive impairment preventing questionnaire completion\n* Pregnancy (if considered clinically relevant)",{"count":151,"type":20},146,[23],"This multicenter randomized controlled trial aims to evaluate the effectiveness of a multimodal intervention for the active management of persistent musculoskeletal pain in primary care. The intervention combines pain neuroscience education, therapeutic exercise, and the promotion of self-care and healthy lifestyle habits to improve health-related quality of life in adults with persistent nonspecific musculoskeletal pain lasting at least six months.\n\nA total of 146 participants aged 18 to 70 years will be recruited from five primary care centers in the Comunitat Valenciana (Spain) and randomly assigned to either the experimental group or the control group. The primary outcome is health-related quality of life measured using the SF-36 Health Survey. Secondary outcomes include pain intensity, pain catastrophizing, kinesiophobia, central sensitization, emotional symptoms, perceived social support, medication use, and lifestyle-related variables. Assessments will be conducted at baseline, post-intervention, 6 months, and 12 months follow-up.",[155],"Chronic Musculoskeletal Pain",[157,158,159,160,161,162,163],"Physical exercise","Patient Care Group","Primary Health Care","Multimodal Intervention","Health-Related Quality of Life","Self-Management","Pain Neuroscience Education","2026-03-06",{"date":166,"type":44},"2026-03-10",{"date":117,"type":20},{"date":169,"type":20},"2028-01",{"name":50,"class":51},5,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":90,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},"100587725","technology-supported-interventions-for-prolonged-grief-disorder-pgd-100587725","NCT06932120","Technology-supported Interventions for Prolonged Grief Disorder (PGD)","Technology-supported Interventions for Prolonged Grief Disorder in Adults a Randomized Controlled Trial","Inclusion Criteria:\n\n* Being at least 18 years old.\n* Meeting diagnostic criteria for Prolonged Grieft Disorder based on the International Classification of Diseases 11 edition (ICD-11).\n* Sign an informed consent.\n* Ability to understand and read Spanish.\n* Ability to use a computer.\n* Having an e-mail address.\n* Having an internet connection and Access to a Smartphone.\n\nExclusion Criteria:\n\n* Presence of high risk of suicide.\n* Presence of axis I severe mental disorder: substance abuse or dependence, psychotic disorder, dementia, bipolar disorder; severe personality disorder or medical illness whose severity or characteristics prevent treatment.\n* Receiving other psychological treatment during the study.\n* An increase and\u002For change in the medication during the study period, in the case of receiving pharmacological treatment.",{"count":180,"type":20},141,[23],"The main aim of this project is to test the efficacy of two formats of delivering an internet- based treatment(GROw) for Prolonged Grief Disorder (PGD) in order to enhance treatment adherence: in a blended format (that combines self-applied treatment online with face-to face sessions with a therapist by videoconference: BF-GROw) and self-applied online format supported by Ecological Momentary Assessment (EMAs) and Ecological Momentary Interventions (EMIs) (iGROw), compared with a waiting list (WL) control group in a community sample of patients with the diagnosis of PGD. The general initial hypothesis is that both treatment conditions (blended format and self-applied format supported by EMAs and EMIs) will significantly produce an improvement in grief symptoms, compared to the WL control group.",[184],"Prolonged Grief Disorder (PGD)",[186,187,188,189,190,191,192],"Prolonged grief disorder","Efficacy","Randomized controlled trial","Internet-based treatment","blended intervention","Ecological Momentary Assessment (EMA)","Ecological Momentary Intervention (EMI)","2026-01-19",{"date":195,"type":44},"2026-01-21",{"date":197,"type":44},"2025-11-10",{"date":199,"type":20},"2027-09-30",{"name":50,"class":51},2,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100616001","multimodal-physiotherapy-and-pain-coping-in-primary-care-100616001","NCT07299929","Multimodal Physiotherapy and Pain Coping in Primary Care","Multimodal Physiotherapy Intervention for Active Coping With Persistent Musculoskeletal Pain in Primary Care","Inclusion Criteria:\n\n\\- Persistent nonspecific musculoskeletal pain lasting at least 6 months\n\nExclusion Criteria:\n\n* Oncologic pain.\n* Spinal fracture or surgical intervention within the 12 months prior to the intervention.\n* Cognitive impairment that prevents comprehension of the intervention content (in case of doubt, the Mini-Mental State Examination will be administered, requiring a minimum score of 25).\n* Physical performance deficit that prevents execution of the intervention (minimum requirement: completion of the Timed Up and Go test within the normal time of 10 seconds).\n* Pregnancy.\n* Cauda equina syndrome.\n* Presence of urinary and\u002For fecal incontinence.\n* Severe psychiatric disorders.\n* Autoimmune diseases.\n* Associated medical conditions that preclude participation in a physical exercise program (e.g., myopathies, neurological diseases with significant functional impairment).\n* Patients undergoing alternative therapies.\n* Patients with an implanted neurostimulator.",{"count":210,"type":20},68,[23],"This quasi-experimental, multicenter study aims to evaluate the effectiveness of a multimodal physiotherapy intervention-based on pain neuroscience education and therapeutic exercise-on health-related quality of life in patients with persistent musculoskeletal pain treated in Primary Care.\n\nThe study will be conducted in four Primary Care physiotherapy units in the Valencian Community (Spain). A total of at least 68 participants aged 18 to 70 years with nonspecific persistent musculoskeletal pain lasting at least six months will be recruited.\n\nThe intervention will consist of a structured multimodal physiotherapy program including educational sessions on pain neuroscience and guided therapeutic exercise. The main outcome will be health-related quality of life, assessed using the SF-36 Health Survey. Secondary outcomes will include pain catastrophizing (Pain Catastrophizing Scale), kinesiophobia (Tampa Scale for Kinesiophobia), and central sensitization (Central Sensitization Inventory), among others.\n\nData will be collected using the REDCap electronic platform at three time points: baseline (pre-intervention), immediately after the intervention, and six months post-intervention. Statistical analysis will include descriptive statistics, bivariate analyses, and paired comparisons to assess changes over time.\n\nThe study seeks to generate evidence on the feasibility and potential effectiveness of implementing a multimodal physiotherapy intervention for active coping with chronic musculoskeletal pain in the context of Primary Care.",[155],"2025-12-09",{"date":216,"type":44},"2025-12-23",{"date":218,"type":20},"2026-09",{"date":220,"type":20},"2027-09",{"name":50,"class":51},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100608547","re-scale-rehabilitation-engagement-and-scaled-access-with-extended-reality-and-artificial-intelligence-100608547","NCT07202975","RE-SCALE: Rehabilitation Engagement and Scaled Access With eXtended Reality and Artificial Intelligence","Inclusion Criteria:\n\n* Age range: Adults over 18 and under 70\n* Diagnosis of chronic low back pain with or without radiculopathy\n* Minimum of moderate disability (21% ODI score)\n* Acceptance of participation and signed consent form\n* Internet access at home\n\nExclusion Criteria:\n\n* History of spinal surgery or fracture\n* Signs of upper motor neuron injury: bilateral paresthesia, hyperreflexia, or spasticity, or other negative signs such as fractures\n* Other severe medical or psychological conditions that prevent participation in the trial.",{"count":229,"type":20},314,[23],"Background Chronic musculoskeletal pain, especially chronic low back pain (CLBP), is the leading cause of disability worldwide, with a burden expected to rise due to aging and increased longevity. Despite strong evidence supporting multimodal and non-pharmacological management-particularly active physical therapy and self-management-clinical practice still shows low adherence to guidelines, with excessive reliance on imaging, rest, injections, and surgery.\n\nAdherence to physical therapy remains one of the most significant barriers: only 40-50% of patients follow prescribed exercise programs. Factors include kinesiophobia, low motivation, and logistical obstacles. Mixed realities (XR: VR, AR, MR) offer solutions by enhancing motivation, reducing barriers, and personalizing rehabilitation. Evidence from systematic reviews shows VR-based rehabilitation can reduce pain, disability, and kinesiophobia, with immersive VR offering additional benefits like presence and habit-building.\n\nThe SHARESPACE project developed and tested a novel XR rehabilitation environment for CLBP that integrates immersive VR\u002FAR, tele-rehabilitation, real-time motor tracking, avatars for social support, and cognitive architectures for synchronization. Usability studies with patients, clinicians, and the general population confirm its feasibility and acceptance. SHARESPACE has completed phases 1 and 2 of XR intervention development (design and feasibility), now aiming to move to phase 3: large-scale clinical validation.\n\nObjectives The main goal is to evaluate not only short-term efficacy but long-term, as well as including more accurate and objective measures. A second objective is the commercial exploitation WE will valuate the efficacy, adherence, and cost-effectiveness of the SHARESPACE XR rehabilitation system compared to usual care in patients with CLBP.\n\nSpecific objectives include:\n\n1. To conduct a two-site randomized controlled trial (RCT) comparing XR rehabilitation with conventional group rehabilitation.\n2. To assess both short-term and long-term outcomes (pain intensity, disability, kinesiophobia).\n3. To monitor and improve adherence through ecological momentary assessment and intervention (EMA\u002FEMI) using an app and activity trackers.\n4. To enhance motivation and engagement with gamification, social connectedness, and avatar-based interaction.\n5. To generate evidence for commercial exploitation and integration into health systems.\n\nMethodology\n\nThe project will conduct a two-site RCT with CLBP patients. Participants will be randomly allocated to:\n\n* XR rehabilitation:\n\n  * Two hospital sessions (traditional + XR-assisted training).\n  * Four remote XR sessions with therapist and patients (L1 avatars).\n  * Continued home-based XR with automated therapist avatars (L3) for up to 120 days.\n  * Integration of EMA\u002FEMI via an app and wearable devices to monitor daily activity, sleep, and adherence, with automated prompts to encourage compliance.\n* Usual care: standard group rehabilitation sessions for 8 weeks.\n\nPrimary outcomes:\n\n* Pain intensity (VAS, BPI).\n* Disability (Oswestry Disability Index).\n* Kinesiophobia (Tampa Scale of Kinesiophobia). Secondary outcomes: adherence rates, motivation, patient satisfaction, feasibility, and cost-effectiveness. Motor performance data will be captured in real time via XR tracking and transmitted to therapists for feedback.",[233],"Chronic Low Back Pain (CLBP)","2025-09-23",{"date":236,"type":44},"2025-10-02",{"date":238,"type":20},"2027-01-01",{"date":240,"type":20},"2027-12-31",{"name":50,"class":51},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":81},"100596873","hablar-self-applied-online-training-for-correcting-emotional-reasoning-biases-in-public-speaking-anxiety-100596873","NCT07051135","HablaRÉ: Self-applied Online Training for Correcting Emotional Reasoning Biases in Public Speaking Anxiety.","HablaRÉ: Self-applied Online Training for Correcting Emotional Reasoning Biases in Public Speaking Anxiety. A Feasibility, Non-randomised Pilot Study.","Inclusion Criteria:\n\n1. Be of legal age.\n2. Accept the informed consent.\n3. Adequately understand\u002Fread Spanish.\n4. Have access to a mobile device or computer with an Internet connection.\n5. Not receiving any other psychological treatment for public speaking anxiety during the study period.\n6. Have a score of 43 or higher on the Emotional reasoning scale (ERPSAS) AND\u002FOR a score of 55 or higher on the Spanish version of the Public Speaking Anxiety Scale (PSAS-S) for fear of public speaking.\n7. If taking prescribed medication for anxiety\u002Fdepression, have had no changes in dosage for at least one month before the procedure.\n\nExclusion Criteria:\n\n1. Not accepting the informed consent.\n2. Being a minor.\n3. Having a severe mental disorder (bipolar disorder, schizophrenia, or other psychotic disorders) or substance abuse (alcohol or other substances) or having active suicidal plans (suicide item in the ODSIS depression questionnaire ≥ 2) that would prevent participation in the program.\n4. In the case of receiving medication, changes in medication during treatment will be evaluated but will not lead to exclusion.",{"count":250,"type":20},20,[23],"The project aims to assess the feasibility of self-administered training for individuals with public speaking anxiety, specifically targeting the reduction of emotional reasoning bias. It seeks to evaluate the interventions' usability, acceptability, satisfaction and adherence\u002Fcompliance rates. In addition, the study intends to determine the feasibility of conducting a potential randomised clinical trial to evaluate the true impact of the intervention on emotional reasoning biases and public speaking anxiety levels.",[254],"Public Speaking Anxiety",[256,254,27,71,257,258,259],"Emotional Reasoning","Feasibility","Internet intervention","Psychological treatment","2025-06-26",{"date":262,"type":44},"2025-07-03",{"date":264,"type":44},"2025-05-01",{"date":266,"type":20},"2025-09",{"name":50,"class":51},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":21,"phases":277,"briefSummary":278,"conditions":279,"keywords":284,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":81},"100576655","analyzing-the-benefits-of-using-symptoms-jit-for-in-vivo-exposure-in-anxiety-disorders-100576655","NCT06788119","Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders","Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders: a Randomized Controlled Trial Using a Mixed Methods Approach","Inclusion Criteria:\n\n* Being at least 18 years or older.\n* Meeting DSM-5 diagnostic criteria (APA, 2013) for anxiety disorder, specifically specific phobia, agoraphobia, panic disorder and social phobia.\n* Being willing to follow the study conditions.\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Having another psychological problem that requires immediate attention.\n* Having current alcohol or drug dependence or abuse, psychosis or severe organic illness.\n* Currently being treated in a similar treatment program.\n* Taking anxiolytics during the study (or in the case of taking them, changing drug or dose during the study).",{"count":276,"type":20},158,[23],"The aim of this study is to develop and test the efficacy of first-of-its-kind, fully instrumented sensor-based smartphone-guided in-vivo exposure therapy using a just-in-time intervention for anxiety disorder. The main hypotheses are:\n\n1. Both treatment conditions (CBT treatment with IVE and CBT treatment with IVE+SYMPTOMS-JIT) will show efficacy and no statistically significant differences will be found between them. The efficacy will be determined for the differences in pre-post treatment in the used outcome measures.\n2. The therapeutic gains obtained in both treatment conditions (IVE and (IVE+SYMPTOMS-JIT) will be maintained at 1-, 6-, and 12-month follow-up periods.\n3. Both treatment conditions will be efficient, that is, they will be well-valued by patients and therapists. However, IVE+SYMPTOMS-JIT will be preferred and perceived as less aversive than IVE.\n4. The main barriers for the use of this technology are not technological, but rather attitudinal and they can be identified through qualitative studies.",[64,280,281,282,283],"Specific Phobia","Panic Disorder","Agoraphobia","Social Anxiety Disorder",[285,286,287,288,289],"Anxiety disorders","In vivo exposure","app","smartphone","smartwatch","2025-05-12",{"date":292,"type":44},"2025-05-16",{"date":294,"type":44},"2025-04-30",{"date":240,"type":20},{"name":50,"class":51},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":90,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":4},"100580613","effectiveness-of-immersive-virtual-reality-in-nursing-students-learning-100580613","NCT06839573","Effectiveness of Immersive Virtual Reality in Nursing Students' Learning","Effectiveness of Immersive Virtual Reality to Improve Learning Outcomes in Nursing Degree Students: A Randomized Clinical Trial","UBUJIRV25","Inclusion Criteria:\n\n\\- having completed the scheduled in-person simulation in previous years of the degree .\n\nExclusion Criteria:\n\n-the student does not sign the informed consent to participate in the study.",{"count":306,"type":20},140,[23],"Teaching using VR for basic cardiopulmonary resuscitation and patient examination (experimental group) will not result in differences in knowledge and skill acquisition compared to traditional classroom-based simulation teaching (control group), but it will lead to greater satisfaction and self-confidence. Open, single-center randomized clinical trial involving fourth-year nursing degree students at a public university. Participants will be assigned based on their usual teaching groups (ratio of 6-8 students per instructor) and, according to randomization, will receive a 1:1 assignment to either the control group (classroom-based simulation teaching) or the experimental group (classroom-based simulation teaching combined with VR headset teaching). The CONSORT checklist will be followed to report the study.",[310],"Informed Consent",[312,313,314,315],"Virtual reality","nursing students","Learning Outcomes","Inmersive virtual reality","2025-02-19",{"date":318,"type":44},"2025-02-21",{"date":320,"type":20},"2025-03-05",{"date":322,"type":20},"2025-05-08",{"name":50,"class":51},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":81},"100531112","application-and-effectiveness-of-the-stepps-in-patients-with-bpd-extending-to-their-families-with-the-fc-program-100531112","NCT06195553","Application and Effectiveness of the STEPPS in Patients with BPD, Extending to Their Families with the FC Program","Application and Analysis of the Effectiveness of the STEPPS Program in Patients with BPD, Extending to Their Families with the Family Connections Program: a Randomized Controlled Trial","PATIENTS\n\nInclusion Criteria:\n\n* Being at least 18 years old.\n* Be a patients with symptoms compatible with a diagnosis of BPD who is undergoing treatment or follow-up in someone of the indicated recruitment centers.\n* Sign an informed consent.\n\nExclusion Criteria:\n\n* The presence of any pathology that prevents carrying out the intervention: major depression, psychosis, schizophrenia, substance dependence, eating disorders, another personality disorder, borderline IQ, etc., which due to its severity is currently interfering.\n\nFAMILIES:\n\nInclusion Criteria:\n\n* Being at least 18 years old.\n* Be a relative of someone of the patients with symptoms compatible with a diagnosis of BPD who is undergoing treatment or follow-up in someone of the indicated recruitment centers.\n* Sign an informed consent.\n\nExclusion Criteria:\n\n* The presence of any pathology that prevents carrying out the intervention: major depression, psychosis, schizophrenia, substance dependence, eating disorders, another personality disorder, borderline IQ, etc., which due to its severity is currently interfering.",{"count":332,"type":20},120,[23],"The present research project is framed within the issue of Borderline Personality Disorder (BPD). This condition stands as one of the most common challenges encountered within the mental health services of the National Health System. The primary objectives of this research are to verify whether the combined use of established treatments for patients and their families, conducted in parallel, leads to a greater improvement in patients and their families, respectively. Additionally, another aim of the project is to assess efficiency, defined as the acceptance of intervention programs by patients, their families, and clinical professionals, as well as to demonstrate their feasibility.",[336],"Borderline Personality Disorder (BPD)",[338,339,340,341,342,343,344],"Personality disorder","borderline personality disorder","stepps","family connections","family focused therapy","family involvement","randomized controlled trial","2025-01-13",{"date":347,"type":44},"2025-01-15",{"date":349,"type":44},"2024-01-02",{"date":351,"type":20},"2026-07-01",{"name":50,"class":51},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":21,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":4},"100558527","online-psychotherapy-for-emotional-reasoning-bias-in-public-speaking-anxiety-100558527","NCT06552273","Online Psychotherapy for Emotional Reasoning Bias in Public Speaking Anxiety","Implementation of a Self-applied Online Psychological Intervention for Emotional Reasoning Bias in People With Public Speaking Anxiety: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Be of legal age.\n2. Accept the informed consent.\n3. Adequately understand\u002Fread Spanish.\n4. Have access to a mobile device or computer with an Internet connection.\n5. Not receiving any other psychological treatment for public speaking anxiety during the study period.\n6. Have a score of 43 or higher on the Emotional reasoning scale (ERPSAS) AND a score of 55 or higher on the Spanish version of the Public Speaking Anxiety Scale (PSAS-S) for fear of public speaking.\n7. If taking prescribed medication for anxiety\u002Fdepression, have had no changes in dosage for at least one month before the procedure.\n\nExclusion Criteria:\n\n1. Not accepting the informed consent.\n2. Being a minor.\n3. Having a severe mental disorder (bipolar disorder, schizophrenia, or other psychotic disorders) or substance abuse (alcohol or other substances) or having active suicidal plans (suicide item in the ODSIS depression questionnaire ≥ 2) that would prevent participation in the program.\n4. In the case of receiving medication, changes in medication during treatment will be evaluated but will not lead to exclusion.",{"count":276,"type":20},[23],"The study aims to develop and implement a self-applied online psychological intervention for the correction of Emotional Reasoning bias for people with public speaking anxiety. By comparing the effects of this training for ER biases vs. a non-specific mindfulness intervention, the newly developed intervention is expected to promote a greater reduction in emotional reasoning bias and the severity of symptomatology associated with public speaking anxiety.",[254],[365,366,367,258,368,188,369,370,371],"Bias correction training","Emotional reasoning","Public speaking anxiety","Self-applied intervention","Scared of speaking in public","Transdiagnostic process","Social anxiety","2024-09-09",{"date":374,"type":44},"2024-09-19",{"date":376,"type":20},"2024-11-01",{"date":378,"type":20},"2025-11-01",{"name":50,"class":51},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":90,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":21,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":81},"100405745","effectiveness-of-a-projection-based-augmented-reality-exposure-system-in-treating-cockroach-phobia-100405745","NCT04563390","Effectiveness of a Projection-based Augmented Reality Exposure System in Treating Cockroach Phobia.","Effectiveness of a Projection-based Augmented Reality Exposure System in Treating Cockroach Phobia. A Randomized Controlled Trial","Inclusion Criteria:\n\n* Being at least 18 years old\n* Meeting DSM-5 diagnostic criteria for SP (animal subtype) to cockroaches\n* Having a minimum of six-month duration of the phobia\n* Sign an informed consent\n* Presenting a score of at least 4 on the fear and avoidance scales of the diagnostic interview applied\n\nExclusion Criteria:\n\n* Presence of another severe mental disorder that requires immediate attention\n* Having current alcohol or drug dependence or abuse, psychosis or severe organic illness\n* Currently being treated in a similar treatment program\n* Being capable of inserting their hands in a plastic container with a cockroach (during the behavioral test)\n* Receiving other psychological treatment during the study for cockroach phobia\n* Start receiving pharmacological treatment during the study (or in case of being already taking them, change the drug or dose)",{"count":388,"type":20},96,[23],"The main aim of this study is to validate and test the clinical effectiveness of the projection-based augmented reality system in cockroach phobia exposure therapy through an RCT that includes three conditions: (i) projection-based augmented reality therapy, (ii) usual treatment (in vivo exposure), (iii) waiting list control. In addition, it is intended to analyze the potential of the eye-tracking technology as a tool for evaluating the clinical effectiveness in cockroach phobia treatment.",[280],[393,394,395,286,396,397],"Specific phobia","Cockroach phobia","Exposure therapy","Projection-Based augmented reality therapy","Randomized Controlled Trial","2024-05-17",{"date":398,"type":44},{"date":401,"type":44},"2020-11-01",{"date":403,"type":20},"2026-07-31",{"name":50,"class":51},""]